Filing Details
- Accession Number:
- 0001209191-17-029621
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-05-03 16:08:07
- Reporting Period:
- 2017-05-02
- Filing Date:
- 2017-05-03
- Accepted Time:
- 2017-05-03 16:08:07
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
907654 | Arca Biopharma Inc. | ABIO | In Vitro & In Vivo Diagnostic Substances (2835) | 363855489 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1113661 | J Daniel Mitchell | 11080 Circlepoint Road Suite 140 Westminster CO 80020 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-05-02 | 11,000 | $2.71 | 11,000 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Footnotes
- The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from$2.65 to $2.75. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting personwill provide full information regarding the number of shares purchased at each separate price.